Aramis FluVac
Seasonal Influenza
PreclinicalActive
Key Facts
About Aramis Biotechnologies
Plant‑based vaccine platform delivering rapid, low‑cost biologics for infectious disease.
View full company profileTherapeutic Areas
Other Seasonal Influenza Drugs
| Drug | Company | Phase |
|---|---|---|
| Nasovac‑S™ | BioDiem | Commercial |
| DeFluvac | BioDiem | Commercial |
| Vaxine Flu Vaccine | Vaxine | Phase 2/3 |
| MF59-Adjuvanted Seasonal Vaccines | CSL Seqirus | Marketed |
| Flucelvax Quadrivalent (cell-based) | CSL Seqirus | Marketed |
| Flublok Quadrivalent (recombinant) | CSL Seqirus | Marketed |
| mRNA-based Influenza Vaccine | Sanofi | Phase 3 |
| mRNA-1010/1011 | Moderna | Phase 3 |
| Standalone Seasonal Influenza Vaccine | Novavax | Phase 3 |
| AdFlu‑Q | Adimmune | Preclinical |
| LUNAR®-FLU (ARCT-2138) | Arcturus Therapeutics | Phase 1 |
| Oral Influenza Vaccine | Vaxart | Phase 2 |